Bristol Myers Squibb

Q2 FY2026 EarningsQ2 FY26 results significantly beat consensus across all key financial metrics, driven by a 15% YoY surge in the Growth Portfolio and 22% growth in Eliquis. Revenue reached $13.0B vs. the $11.7B expected, while non-GAAP EPS of $2.04 far exceeded the $1.60 consensus. Bolstered by broad-based momentum, management raised full-year FY26 revenue guidance to $49B-$50B and increased the non-GAAP EPS outlook to $6.75-$7.00.